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Abstract We used the yeast two-hybrid system to show that the
serum response factor (SRF) and zinc-fingers and homeobox 1
(ZHX1) proteins interact with the A subunit of nuclear factor-Y
(NF-YA). GST pulldown assays revealed that both proteins
interact specifically with NF-YA in vitro. Amino acids located
between 272 and 564, a region that contains two homeodomains,
are required for the interaction of ZHX1 with NF-YA. Two
different domains of NF-YA, a glutamine-rich region and a
serine/threonine-rich region, are necessary for the interactions
with ZHX1 and SRF, respectively.
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1. Introduction
Nuclear factor-Y (NF-Y), also referred to as CCAAT bind-
ing factor, stimulates gene transcription from many promoters
by binding to an inverted CCAAT box [1]. NF-Y, a ubiqui-
tous heteromeric protein, is composed of three subunits, NF-
YA, NF-YB, and NF-YC. NF-YB and NF-YC tightly inter-
act with each other and their association precedes the associ-
ation with NF-YA and the subsequent binding of the complex
to the cognate DNA sequences [2]. NF-YB and NF-YC in-
teract with other transcription factors or co-activators [3^6],
but little is known about whether NF-YA interacts with pro-
teins other than NF-YB and NF-YC.
To analyze the molecular mechanism of transcription acti-
vation by NF-Y, we determined whether the activation do-
main (AD) of NF-YA interacts with either a known or a
novel transcription factor. Here we report the detection of
zinc-¢ngers and homeobox 1 (ZHX1) and serum response
factor (SRF) as NF-YA-interacting proteins, determine the
minimal interaction domain of ZHX1 required for the asso-
ciation with NF-YA, and show that two di¡erent domains of
NF-YA interact with SRF or ZHX1, respectively.
ZHX1 cDNA was isolated from a mouse library [7]. ZHX1
consists of 873 amino acids and contains two C2-H2 type zinc-
¢ngers (Znf) and ¢ve homeodomains (HD). The mouse ZHX1
cDNA was cloned as a nuclear antigen recognized by the B92
monoclonal antibody, which was produced by immunization
with cell lysates of the 14F1.1 mouse endothelial-adipose stro-
mal cell, but the physiological role of this protein has not been
determined [8].
The function of SRF is well-characterized. This transcrip-
tion factor binds to and transactivates from the serum re-
sponse element of the c-fos gene promoter [9,10]. Transacti-
vation by serum stimuli is dependent upon the
phosphorylation of p62TCF/Elk-1, which forms a ternary com-
plex with SRF [9,10].
2. Materials and methods
2.1. Materials
The yeast two-hybrid system and human liver MATCHMAKER
cDNA library were purchased from Clontech. Glutathione-agarose
was purchased from Sigma. pGEX-5X-1 and Thermo Sequenase II
dye terminator cycle sequencing kit were obtained from Amersham
Pharmacia Biotech. TOPP3 cells and pET-3a were purchased from
Stratagene. TRAN35SLABEL (43.48 TBq/mmol) was purchased
from ICN.
2.2. Oligonucleotides
All oligonucleotides used in this study were prepared with a DNA
synthesizer. The nucleotide sequences are as follows: GSTzhx1s,
5P-AATTCATGGCAAGCCAG-3P ; GSTzhx1as, 5P-AATTCTGG-
CTTGCCATG-3P ; ACT2-zhx1s, 5P-AATTATGGCAAGCCAG-3P ;
ACT2-zhx1as, 5P-AATTCTGGCTTGCCAT-3P ; ACT2B1s, 5P-CAT-
GGAGGCCCCGGGATCCG-3P ; ACT2B1as, 5P-AATTCGGATC-
CCGGGGCCTC-3P ; 272zhx1s, 5P-CCGGGGATCCAATTCTAAT-
TTGATTCCCAAAGTC-3P ; 345zhx1s, 5P-CCGGGGATCCCCCG-
AGGAAGTAGAGGAGG-3P ; 430zhx1s, 5P-CCGGGGATCCCA-
GGTACCTGCTGCTCAGC-3P ; 565zhx1s, 5P-CCGGGGATCCCT-
GACTTTACTCCCCAAAAG-3P ; 432zhx1as, 5P-CCGGGGATCCC-
TAAGGTACCTGACTTTTCTGTATA-3P ; 463zhx1as, 5P-CCGG-
GGATCCCTAATCAGGGTTTACCAATGCAGTT-3P ; 564zhx1as,
5P-CCGGGGATCCCTAAAAAGGATTCCAGGATTGCTTAG-3P ;
873zhx1as, 5P-GGGTATTGGATCCTGCTTTTTG-3P ; GAL4BD, 5P-
TCATCGGAAGAGAGTAGTAAC-3P ; YA31s, 5P-CCGGCATAT-
GGTCACTGCTGTCCAGCTGC-3P ; YA61s, 5P-CCGGCATATGG-
TGCAAGTCAGTGGAGG-3P ; YA141s, 5P-CCGGCATATGGT-
CACCGCTGGCCAGGGA-3P ; YA172s, 5P-CCGGCATATGAACA-
CAACCAGTAGTGGACAAG-3P ; YA205s, 5P-CCGGCATATGC-
CAGTTAATGCAGATGGCAC-3P ; YA269as, 5P-CCGGGGATC-
CTCAAAGGATGCGGTGATACTGTTTG-3P ; YA204as, 5P-CCG-
GGGATCCTCAGGTATTGGCTCCTGTCTGAA-3P ; YA140as, 5P-
CCGGGGATCCTCACGCGGTCTGTGGCTGCTG-3P ; YA112as,
5P-CCGGGGATCCTCACTGTCCAGGGGGTACCAAC-3P ; 412-
SRFs, 5P-CCGGGGATCCCCGCATGCGGTGATGTATGC-3P ; and
508SRFas, 5P-CCGGGGATCCTCATTCACTCTTGGTGCTGT-3P.
2.3. Plasmid construction
pACT2-#111, pBSII-hZHX1E/X, pGBT9(N/R/N), and pGBT9(N/
R/N)NF-YA1^269 plasmids were previously described [11]. An
EcoRI/XhoI fragment of pBSII-hZHX1E/X was isolated and sub-
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cloned into the EcoRI/XhoI sites of the pGST-5X-1 to obtain pGST-
ZHX1E/X. GST-zhx1s and GST-zhx1as oligonucleotides were an-
nealed and phosphorylated. The double-stranded oligonucleotide
was inserted into the EcoRI site of the pGST-ZHX1E/X to produce
pGST-ZHX1(272/873), which expresses the amino acid sequence be-
tween 272 and 873 of ZHX1 ligated to glutathione S-transferase
(GST). We employed the following method for construction of
GAL4 AD-fusion protein expression vectors. The ACT2-zhx1s and
ACT2-zhx1as oligonucleotides were annealed and phosphorylated.
The pACT2-#111 was digested with EcoRI to remove a 390-bp insert
that encodes amino acids 142^271 of ZHX1. The double-stranded
oligonucleotide was ligated into the EcoRI site of this plasmid to
obtain pZHX1(272^873). The pACT2 vector was digested with NcoI
and EcoRI. The ACT2B1s and ACT2B1as oligonucleotides were an-
nealed, phosphorylated, and ligated into the NcoI/EcoRI site of the
pACT2 to produce the pACT2B1 plasmid. A polymerase chain reac-
tion (PCR) was carried out using pBSII-hZHX1E/X as a template and
the following combinations of primers: 565zhx1s and 873zhx1as,
272zhx1s and 564zhx1as, 272zhx1s and 432zhx1as, 430zhx1s and
564zhx1as, and 345zhx1s and 463zhx1as. The products were sub-
cloned into pT7-blue T vector, and the nucleotide sequences were
determined. The resultant plasmids were digested with BamHI. After
isolation by agarose gel electrophoresis, these fragments were ligated
into the BamHI site of pACT2B1, to produce pZHX1(565^873),
pZHX1(272^564), pZHX1(272^432), pZHX1(430^564), and
pZHX1(345^463), respectively. We also constructed GAL4 DNA
binding domain (DBD) fusion protein expression vectors. PCR was
carried out using the pGBT9(N/R/N)NF-YA1^269 as a template and
the following combinations of primers: GAL4BD and YA204as,
GAL4BD and YA140as, GAL4BD and YA112as, YA31s and
YA140as, YA61s and YA140as, YA31s and YA269as, YA61s and
YA269as, YA141s and YA269as, YA172s and YA269as, and
YA205s and YA269as to produce pYA1^204, pYA1^140, pYA1^
112, pYA31^140, pYA61^140, pYA31^269, pYA61^269, pYA141^
269, pYA172^269, and pYA205^269, respectively. pcDNA3/His-
SRF was a gift from Dr. Linda Sealy (Vanderbilt University). The
EcoRI fragment of the pcDNA3/His-SRF encoding an open reading
frame of SRF was subcloned into the EcoRI site of the pGEX-5X-1 to
produce the pGST-SRF. PCR was carried out using pcDNA3/His-
SRF as a template with a combination of 412SRFs and 508SRFas
primers. Ampli¢ed DNA was digested with BamHI and subcloned
into the BamHI site of the pACT2B1 to produce pSRF(412^508).
cDNA fragments that contain the open reading frame of NF-YA
and NF-YB with NdeI and EcoRI ends were ampli¢ed by PCR for
use in the in vitro transcription/translation system. These products
were digested with NdeI and EcoRI and subcloned into the NdeI/
EcoRI sites of pET-3a to obtain NF-YAWET3a and NF-YBWET3a,
respectively. The nucleotide sequences of these constructs were deter-
mined by an automated DNA sequencer (PE Applied 373A DNA
sequencer).
2.4. Yeast two-hybrid assays
HF7c or SFY526 cells were transformed with the indicated bait
plasmid by a TE/LiAc-based high e⁄ciency transformation method
[12]. Human liver cDNA library screening, using the pGBT9(N/R/
N)NF-YA1^269 bait plasmid, was performed as described [11].
HF7c cells harboring a bait plasmid were transformed with the indi-
cated GAL4 AD expression plasmids for use in HIS3 reporter gene
assays. SFY526 cells harboring the indicated bait plasmid were trans-
formed with various GAL4 AD expression plasmids for use in
L-galactosidase assays. Quantitative L-galactosidase assays, using
o-nitrophenyl-L-D-galactoside as the substrate, were carried out on
permeabilized cells [13].
2.5. GST binding assays
TOPP3 cells were transformed with pGEX-5X-1, pGST-ZHX1(272/
873), or pGST-SRF. The preparation of the GST fusion protein, and
the GST binding assays, were performed as described [11].
3. Results
3.1. Isolation of NF-YA-interacting proteins in a
yeast two-hybrid library screen
The amino acid sequence 1^269, which encodes the AD but
not the DBD or subunit interaction domain (SID) of NF-YA
[14], was fused to the GAL4 DBD and this chimeric protein
was employed as the bait to screen a human liver cDNA
library using the yeast two-hybrid system. Approximately
1U106 independent clones were screened. Three clones,
#111, #112, and #120, showed His and L-gal positive prop-
erties [11]. We isolated plasmids that encode GAL4 AD fusion
protein from these clones and designated them pACT2-#111,
pACT2-#112, and pACT2-#120, respectively. pACT2-#111
encodes the amino acid sequence between 142 and 873 of
human ZHX1 [11]. The nucleotide sequences of pACT2-
#112 and pACT2-#120 are identical to human SRF.
pACT2-#112 and pACT2-#120 contain the nucleotide se-
quence 1078^2640 of SRF, which corresponds to the amino
acid sequence 241^508. This region includes the C-terminal
AD of SRF and the domain that interacts with RAP74 [15].
It does not contain the DBD, dimerization domain, or the
domain required for interaction with p62TCF/Elk-1. Hereafter
pACT2-#111, and pACT2-#112 and pACT2-#120 were
named pZHX1(142^873) and pSRF(241^508), respectively.
We next examined the speci¢city of the interaction between
NF-YA and ZHX1 or SRF using the yeast two-hybrid assay
(Table 1). We employed two bait plasmids, pGBT9(N/R/N)
which expresses the GAL4 DBD, and pGBT9(N/R/N)YA1^
269 which expresses the GAL4 DBD ligated to the AD of
NF-YA, and three prey plasmids, pACT2 which expresses
the GAL4 AD, and pZHX1(142^873) or pSRF(241^508),
which express the GAL4 AD fused to the cloned ZHX1 or
SRF cDNAs, respectively. When the yeast HF7c strain con-
taining pGBT9(N/R/N) was transformed with pACT2,
pZHX1(142^873), or pSRF(241^508), the transformants did
not grow on histidine-free synthetic dextrose (SD-His) plates
(Table 1). Yeast harboring a combination of pGBT9(N/R/
N)YA1^269 and pACT2 also did not grow on SD-His plates.
In contrast, yeast containing a combination of pGBT9(N/R/
N)YA1^269 and pZHX1(142^873) or pSRF(241^508) grew
on SD-His plates. We then determined L-galactosidase activity
in yeast SFY526 strains that harbor the same combina-
Table 1
HIS3 reporter gene expression and L-galactosidase activities of yeast strains harboring various combinations of GAL4 DBD and AD fusion
plasmids
DBD fusion plasmid AD fusion plasmid HIS3 gene expression L-Galactosidase activity (U)
pGBT9(N/R/N) pACT2 No 4.3 þ 0.1
pGBT9(N/R/N) pZHX1(142^873) No 0.5 þ 0.2
pGBT9(N/R/N) pSRF(241^508) No 0.5 þ 0.2
pGBT9(N/R/N)YA1^269 pACT2 No 1.2 þ 0.3
pGBT9(N/R/N)YA1^269 pZHX1(142^873) Yes 46.9 þ 12.7
pGBT9(N/R/N)YA1^269 pSRF(241^508) Yes 115.1 þ 1.9
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tions of plasmids. As shown in Table 1, yeast containing
both pGBT9(N/R/N)YA1^269 and pZHX1(142^873) or
pSRF(241^508) plasmids expressed higher L-galactosidase ac-
tivity than the other yeasts tested. These results indicate that
the AD of NF-YA speci¢cally interacts with ZHX1 and SRF
in vivo.
We next used in vitro GST binding assays to test for an
interaction of NF-YA and ZHX1 or SRF. In vitro translated,
35S-labeled NF-YA or NF-YB was incubated with puri¢ed
GST, GST-ZHX1(272/873) or GST-SRF proteins bound to
glutathione-agarose (Fig. 1). NF-YA bound to GST-
ZHX1(272/873) and GST-SRF, but not to GST alone. In
contrast, NF-YB failed to bind to either protein. These results
indicate that NF-YA speci¢cally interacts with ZHX1 or SRF
in vitro and in vivo.
3.2. Determination of the domain of ZHX1 or SRF that
interacts with NF-YA
Various truncated ZHX1 proteins fused to the GAL4 AD
were expressed in a reporter yeast strain in order to map the
domain of ZHX1 that interacts with the AD of NF-YA. We
used an SFY526 yeast strain harboring the pGBT9(N/R/
N)YA1^269 as the reporter. When the pZHX1(272^873) vec-
tor, which expresses the HD1 through HD5 regions of ZHX1
fused to the GAL4 AD, was transformed into the reporter
yeast, the resultant cells showed a high level of L-galactosidase
activity (Fig. 2A). Yeast transformed with the pZHX1(565^
873) vector, which expresses the HD3 through HD5 regions of
ZHX1 fused to the GAL4 AD, showed no L-galactosidase
activity. In contrast, yeast transformed with pZHX1(272^
564), which expresses the HD1 and HD2 regions of ZHX1,
exhibited high L-galactosidase activity. No L-galactosidase ac-
tivity was detected in yeast transformed with plasmids that
encode either HD1 or HD2, or the internal region between
HD1 and HD2 of ZHX1 fused to the GAL4 AD. These
results indicate that the amino acid sequence located between
272 and 564, and encoding the HD1 and HD2 regions of
Fig. 1. Interaction of NF-YA with ZHX1 or SRF in vitro. In vitro
translated, 35S-labeled NF-YA or NF-YB were incubated with agar-
ose bead-bound GST, GST-ZHX1(272/873) (A) or GST-SRF (B) fu-
sion proteins. The beads were washed thoroughly and bound pro-
teins were analyzed by SDS-PAGE and autoradiography. The signal
in the lane marked ‘1/10 input’ represents 10% of the protein added
to the reactions shown in the other lanes.
Fig. 2. Identi¢cation of the domains of ZHX1 or SRF required for
interaction with NF-YA1^269. A schematic diagram of ZHX1 and
its deletion mutants fused to GAL4 AD is illustrated in A. Znf and
HD indicate the zinc-¢nger domain and homeodomain, respectively.
The GAL4 AD fusion constructs are depicted on the left. A sche-
matic diagram of SRF and its deletion mutant fused to GAL4 AD
is shown in B. DBD, DNA binding domain; AD, activation do-
main; MADS, MADS box. The DBD is shown by a closed box
and the AD is shown by a vertical hatched box. The dimerization
domain and the domains that interact with p62TCF/Elk-1 or RAP74
are shown by horizontal lines at the top. The pSRF(241^508) and
pSRF(412^508) constructs express amino acid sequences 241^508
and 412^508 of SRF ligated to GAL4 AD, respectively. The + and
3 symbols indicate increased (+) and unchanged (3) levels of L-ga-
lactosidase activity, respectively, as compared to a yeast harboring a
combination of pGBT9(N/R/N)YA1^269 and pACT2.
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ZHX1, is essential for the physical interaction with the AD of
NF-YA.
The amino acid sequence between 412 and 508 of SRF is
known to interact with the RAP74 subunit of TFIIF [15]. We
tested whether the same domain of SRF interacts with NF-
YA. pSRF(412^508) expresses the amino acid sequence lo-
cated between 412 and 508 of SRF fused to the GAL4 AD.
Yeast harboring pGBT9(N/R/N)YA1^269 transformed with
the pSRF(412^508) showed no L-galactosidase activity (Fig.
2B). This indicates that the domain of SRF necessary for
interacting with NF-YA is not identical to that required for
the interaction with RAP74.
3.3. Mapping the domains of NF-YA that interact with ZHX1
or SRF
As shown in Fig. 3, the AD of NF-YA consists of a gluta-
mine-rich domain and a serine/threonine-rich domain [14].
Various truncated forms of NF-YA ligated to the GAL4
DBD were prepared to determine which domain is required
for the interaction with ZHX1 or SRF. Yeast strain SFY526
containing pZHX1(142^873) or pSRF(241^508) was used as
the reporter. These cells were transformed with pYA1^204,
which expresses the amino acid sequence 1^204 of NF-YA
ligated to the GAL4 DBD. Interestingly, the yeast harboring
pZHX1(142^873) showed high L-galactosidase activity, but
cells with pSRF(241^508) were inactive. This indicates that
the domain of NF-YA required for the interaction with
ZHX1 is di¡erent from the one that interacts with SRF.
We then determined the minimal domain of NF-YA re-
quired for the interaction with ZHX1. We constructed C-ter-
minal deletion mutants of NF-YA fused to the GAL4 DBD.
pYA1^140 and pYA1^112 express the amino acid sequences
located between 1 and 140 and 1 and 112 of NF-YA, respec-
tively. The reporter yeast transformed with pYA1^140 was the
only one that showed high L-galactosidase activity. This in-
dicates that amino acid segment 1^140 of NF-YA is su⁄cient
for an interaction with ZHX1. Additional de¢nition was ac-
complished by using pYA31^140 and pYA61^140, which ex-
press the amino acid sequences 31^140, and 61^140 of NF-
YA, respectively. Yeast harboring pYA31^140 exhibited high
L-galactosidase activity; pYA61^140 was inactive. These re-
sults indicate that the NF-YA 31^140 amino acid sequence,
which contains a glutamine-rich domain, is the minimal do-
main required for the interaction with ZHX1.
The domain of NF-YA required for an interaction with
SRF was also studied using successive N-terminal deletion
mutants of NF-YA ligated to the GAL4 DBD. pYA31^269,
pYA61^269, pYA141^269, pYA172^269, and pYA205^269
express amino acid segments 31^269, 61^269, 141^269, 172^
269, and 205^269 of NF-YA, respectively. The reporter yeast
harboring pSRF(241^508) was transformed with each of these
plasmids. High L-galactosidase expression was noted in cells
transformed with pYA31^269, pYA61^269, and pYA141^269.
These results indicate that the amino acid sequence located at
positions 141^269 of NF-YA, which contains a serine/threo-
nine-rich domain, is the minimal domain required for the
interaction with SRF.
4. Discussion
ZHX1 and SRF interact with NF-YA. ZHX1 contains two
Znf and ¢ve HDs, and belongs to a divergent homeobox
protein family [7,11]. The ZHX1 amino acid segment 272^
564, which encodes HD1 and HD2, contains the NF-YA-in-
teracting domain. Generally, the HD contains a conserved 60
amino acid motif that functions as a DBD [16]. However, the
HD can also interact with other transcription factors [17^19],
and with proteins not generally considered to be transcription
factors [20,21]. For example, some protein kinases function as
co-repressors by interacting with HD-bound transcription fac-
tors [20]. Also, calreticulin, a chaperone protein, binds to the
HD of thyroid transcription factor-1 and enhances its tran-
scriptional activity [21]. The NF-YA-interacting domain of
ZHX1 might be part of a transcription factor network that
could lead to the discovery of other ZHX1-interacting pro-
tein(s).
Fig. 3. Identi¢cation of the domain of NF-YA that interacts with ZHX1 or SRF. A schematic representation of NF-YA is shown at the top
left. Q and S/T indicate the glutamine-rich and serine/threonine-rich regions, respectively. SID and DBD indicate the subunit interaction and
DNA binding domains, respectively. The GAL4 DBD-NF-YA fusion constructs are depicted on the left. The + and 3 symbols indicate in-
creased (+) and unchanged (3) levels of L-galactosidase activity, respectively, as compared to a yeast harboring a combination of pGBT9(N/R/
N)YA1^269 and pACT2. ND, not determined.
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A synergistic interaction may occur between the Y-box and
the SRE element in the human L-actin and thrombospondin 1
gene promoters [22,23]. Our results show that the proteins
that bind to these elements interact. Although the region of
SRF we cloned contains a RAP74-interacting domain, the
minimal domain of SRF required for the interaction with
NF-YA is not identical with the domain required for SRF-
RAP74 interaction. In contrast, the AD of SRF interacts with
ATF 6 through a domain that is larger than that required for
the SRF-RAP74 interaction [24]. It is possible that the SRF
241^508 domain may interact with both NF-YA and ATF 6.
Two di¡erent domains of NF-YA, the glutamine-rich re-
gion and serine/threonine-rich region, interact with ZHX1
and SRF, respectively. The C-terminal region of NF-YA con-
tains domains that interact with NF-YB and NF-YC, and it
has a DBD. Thus NF-YA has several domains required for
protein-protein interactions and it too may participate in a
complicated transcription factor-network system that involves
several other proteins. Recent reports show that Sp1 and hep-
atocyte nuclear factor 4 (HNF4) are NF-YA-interacting pro-
teins [25,26]. Although the minimal domain required for the
interaction of HNF4 with NF-YA was not determined, the
glutamine-rich region of NF-YA is necessary for the interac-
tion with Sp1 [25]. ZHX1 and SRF can now be added to the
list of NF-YA-interacting proteins.
We postulate that NF-Y is one of the factors involved in
cAMP-mediated transcriptional stimulation of the rat type II
hexokinase gene promoter [27]. SRF activity is induced by
serum stimuli and by cAMP [9,10]. It is possible that inter-
actions between NF-Y and SRF or ZHX1 may be regulated
by cAMP. It remains to be determined whether interactions
among these transcription factors a¡ect the promoter activity
in target genes, if ZHX1 and SRF simultaneously interact
with NF-YA, and if Sp1, in addition to these proteins, can
competitively interact with NF-YA. We are performing ex-
periments to address these questions.
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